The effectiveness of additional rounds of annual 3D-MDA starting in 2023 for three different levels of treatment coverage.

A strategy’s effectiveness is judged by its control probability, the proportion of simulations in which mf prevalence decreased between 2030 and 2035. Treatments are the average number of treatments administered over the duration of MDA and do not include treatment numbers from the prior MDA rounds in 2018, 2019, and 2021. The uncertainty in the control probabilities is quantified with a 95% credible interval.